'Hard' Brexit And Damage To MHRA's EU Medtech Reg Role Causing UK Concern
Executive Summary
Few it seems want the UK MHRA to lose its strong input into EU medtech regulatory affairs. But the UK's brinkmanship on a hard Brexit and refusal to countenance any jurisdiction for the European Court of Justice post-Brexit could spell a severely diminished role for the UK health care regulator in EU matters after March 2019.
You may also be interested in...
UK Device Manufacturers Must Contingency Plan For A Hard Brexit
The compromise tone adopted last week by the UK government on key "phase 1" issues of an EU-UK Brexit deal was welcomed by UK health-care products industries, but with uncertainty over phase 2 – the future EU trade deal – still hampering UK business planning, local companies have no choice but to begin contingencies for a hard Brexit. Overseas stakeholders are also starting to distance themselves from a UK still unable to commit to a post-2019 relationship with the EU27.
Mutual Recognition Post-Brexit? Discussions In Muddled Haze
Discussions continue on whether the UK will take on the EU MDR and IVDR post-Brexit, or whether mutual recognition is way forward. Indecision and misinformation are reducing confidence in a good outcome.
Brexit: Vital Strategies For Keeping Devices On EU And UK Markets
As the Brexit clock ticks, fewer organizations are willing to risk waiting for the political fog to clear, preferring to act now. Lawyer Alison Dennis spells out practical survival strategies.